(Reuters) – French vaccine maker Valneva reported on Thursday a first quarter core earnings loss of 12.3 million euros ($13.63 million), smaller than expected by analysts, helped by increasing sales of its travel vaccines Dukoral and Ixiaro.
The company also confirmed its financial guidance for 2023.
($1 = 0.9027 euros)
(Reporting by Greta Rosen Fondahn and Laura Lenkiewicz; Editing by Muralikumar Anantharaman)
